CA2222140A1 - Packaging systems for human recombinant adenovirus to be used in gene therapy - Google Patents
Packaging systems for human recombinant adenovirus to be used in gene therapyInfo
- Publication number
- CA2222140A1 CA2222140A1 CA002222140A CA2222140A CA2222140A1 CA 2222140 A1 CA2222140 A1 CA 2222140A1 CA 002222140 A CA002222140 A CA 002222140A CA 2222140 A CA2222140 A CA 2222140A CA 2222140 A1 CA2222140 A1 CA 2222140A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cell
- acid molecule
- recombinant nucleic
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Abstract
The invention provides improved methods and products based on adenoviral materials which can advantageously be used in for instance gene therapy. In one aspect an adenoviral vector is provided which has no overlap with a suitable packaging cell line which is another aspect of invention. This combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. In another aspect an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Further a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, which all have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system. Further a method of intracellular amplification is provided.
Claims (21)
1. A recombinant nucleic acid molecule based on or derived from an adenovirus having at least a functional encapsidating signal and at least one functional Inverted Terminal Repeat or a functional fragment or derivative thereof and having no overlapping sequences which allow for homologous recombination leading to replication competent virus in a cell into which it is transferred.
2. A recombinant nucleic acid molecule according to claim 1 being in a linear form and comprising an Inverted Terminal Repeat at or near both termini.
3. A recombinant nucleic acid molecule according to claim 1 being in a linear and essentially single stranded form and comprising at the 3' terminus a sequence complementary to an upstream part of the same strand of said nucleic acid molecule, said sequence being capable of base-pairing with said part in a way to be able to function as a start-site for a nucleic acid polymerase.
4. A recombinant nucleic acid molecule according to claim 3, comprising all adenovirus derived genetic information necessary for replication, except for a functional encapsidation signal.
5. A recombinant nucleic acid molecule derived from the nucleic acid molecule according to claim 4 resulting from the action of a nucleic acid polymerase on said nucleic acid molecule according to claim 4.
6. A recombinant nucleic acid molecule according to claim 5 having an Inverted Terminal Repeat at both termini.
7. A recombinant nucleic acid molecule according to anyone of the aforegoing claims comprising a host range mutation.
8. A recombinant nucleic acid molecule according to anyone of the aforegoing claims, which is a packaging construct and which comprises a mutated E2 region rendering at least one of its products temperature sensitive.
22. A cell according to anyone of claims 10-13, which does not have the ability to express the 21kD E1B product. ~ A
cell according to claim 22, wherein the genetic information encoding the 2lkD E1B product is not present.
24. A cell according to anyone of claims 10-23 which is a diploid cell.
25. A cell according to anyone of claims 10-24 which is of non-human origin.
26. A cell according to anyone of claims 10-25 which is of monkey origin.
27. A cell according to claim 19 as deposited under no. 95062101 at the ECACC.
28. A recombinant nucleic acid molecule according to anyone of claims 1-9 being a DNA molecule.
29. A recombinant nucleic acid molecule based on or derived from an adenovirus, having at least a deletion of nucleotides 459-3510 of the E1 region.
30. A recombinant nucleic acid molecule based on or derived from an adenovirus, having a deletion of nucleotides 459-1713 of the E1 region.
31. An adenovirus-like particle comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
32. A cell comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
33. A recombinant nucleic acid according to claims 1-3, comprising functional E2A end E2B genes or functional fragments or derivatives thereof under control of an E1A
independent promoter.
34. A cell according to claim 26 which comprises a host range mutated E2A region of an adenovirus.
35. A method for intracellular amplification comprising the steps of providing a cell with a linear DNA fragment to be amplified, which fragment is provided with at least a functional part or derivative of an Inverted Terminal Repeat at one terminus and providing said cell with functional E2 derived products necessary for replication of said fragment
22. A cell according to anyone of claims 10-13, which does not have the ability to express the 21kD E1B product. ~ A
cell according to claim 22, wherein the genetic information encoding the 2lkD E1B product is not present.
24. A cell according to anyone of claims 10-23 which is a diploid cell.
25. A cell according to anyone of claims 10-24 which is of non-human origin.
26. A cell according to anyone of claims 10-25 which is of monkey origin.
27. A cell according to claim 19 as deposited under no. 95062101 at the ECACC.
28. A recombinant nucleic acid molecule according to anyone of claims 1-9 being a DNA molecule.
29. A recombinant nucleic acid molecule based on or derived from an adenovirus, having at least a deletion of nucleotides 459-3510 of the E1 region.
30. A recombinant nucleic acid molecule based on or derived from an adenovirus, having a deletion of nucleotides 459-1713 of the E1 region.
31. An adenovirus-like particle comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
32. A cell comprising a recombinant nucleic acid molecule according to anyone of claims 1-9.
33. A recombinant nucleic acid according to claims 1-3, comprising functional E2A end E2B genes or functional fragments or derivatives thereof under control of an E1A
independent promoter.
34. A cell according to claim 26 which comprises a host range mutated E2A region of an adenovirus.
35. A method for intracellular amplification comprising the steps of providing a cell with a linear DNA fragment to be amplified, which fragment is provided with at least a functional part or derivative of an Inverted Terminal Repeat at one terminus and providing said cell with functional E2 derived products necessary for replication of said fragment
9. A recombinant nucleic acid molecule according to claim 8 comprising an E2 region under the control of an inducible promoter.
10. A packaging cell for packaging adenovirus derived nucleic acid molecules, which packaging cell has been provided with one or more recombinant nucleic acid molecules according to claim 1 which provide said cell with the ability to express adenoviral gene products derived from at least the E1A region.
11. A packaging cell according to claim 10 which packaging cell has been provided with one or more recombinant nucleic acid molecules which provide said cell with the ability to express adenoviral gene products derived from at least both the E1A and the E2A region.
12. A packaging cell according to claim 11, wherein the recombinant nucleic acid molecule encoding the E2A region is under control of an inducible promoter.
13. A packaging cell according to claim 11 or 12, wherein the recombinant nucleic acid molecule encoding the E2A region is mutated so that at least one of its products is temperature sensitive.
14. A cell according to anyone of claims 10-13, which does not have the ability to express E1B products.
15. A cell according to claim 14, wherein the genetic information encoding E1B products is not present.
16. A cell according to claim 10, further comprising the region coding for E1B.
17. A cell according to claim 10, further comprising a marker gene.
18. A cell according to claim 17, whereby the marker gene is under control of the E1B responsive promoter.
19. A packaging cell harbouring nucleotides 80-5788 of the human Adenovirus 5 genome.
20. A packaging cell harbouring nucleotides 459-1713 of the human Adenovirus 5 genome.
21. A packaging cell harbouring nucleotides 459-3510 of the human Adenovirus 5 genome.
and allowing said fragment to be acted upon by a DNA
polymerase.
36. A method according to claim 35 whereby the cell is provided with genetic material encoding both E2A and E2B
products.
37. A method according to claim 35 or 36 whereby a hairpin-like structure is provided at the terminus of the DNA
fragment opposite the Inverted Terminal Repeat.
and allowing said fragment to be acted upon by a DNA
polymerase.
36. A method according to claim 35 whereby the cell is provided with genetic material encoding both E2A and E2B
products.
37. A method according to claim 35 or 36 whereby a hairpin-like structure is provided at the terminus of the DNA
fragment opposite the Inverted Terminal Repeat.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95201611 | 1995-06-15 | ||
EP95201611.1 | 1995-06-15 | ||
EP95201728 | 1995-06-26 | ||
EP95201728.3 | 1995-06-26 | ||
PCT/NL1996/000244 WO1997000326A1 (en) | 1995-06-15 | 1996-06-14 | Packaging systems for human recombinant adenovirus to be used in gene therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2222140A1 true CA2222140A1 (en) | 1997-01-03 |
CA2222140C CA2222140C (en) | 2010-11-23 |
Family
ID=26139401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2222140A Expired - Lifetime CA2222140C (en) | 1995-06-15 | 1996-06-14 | Packaging systems for human recombinant adenovirus to be used in gene therapy |
Country Status (15)
Country | Link |
---|---|
US (10) | US5994128A (en) |
EP (2) | EP0833934B2 (en) |
JP (2) | JP4051416B2 (en) |
KR (2) | KR100449181B1 (en) |
AT (2) | ATE445705T1 (en) |
AU (1) | AU731767B2 (en) |
CA (1) | CA2222140C (en) |
DE (2) | DE69633565T3 (en) |
DK (2) | DK0833934T4 (en) |
ES (2) | ES2231813T5 (en) |
HK (1) | HK1064406A1 (en) |
IL (3) | IL122614A0 (en) |
PT (2) | PT1445322E (en) |
SI (2) | SI1445322T2 (en) |
WO (1) | WO1997000326A1 (en) |
Families Citing this family (355)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0872552A1 (en) * | 1997-04-15 | 1998-10-21 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin |
NL9101680A (en) | 1991-10-04 | 1993-05-03 | Tno | METHOD FOR GENETICALLY MODIFYING PRIMATE BONE MARROW CELLS AND USE CELLS PRODUCING RECOMBINANT RETROVIRAL VECTORS. |
FR2705686B1 (en) * | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
US6080569A (en) * | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
DE69533295T3 (en) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-associated antigens, epitopes thereof and melanoma-containing vaccines |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
US6204052B1 (en) | 1994-08-16 | 2001-03-20 | Introgene B.V. | Adenoviral vectors with reduced TNF response and partial E3 region deletion |
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6265212B1 (en) * | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
ATE445705T1 (en) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUSES FOR GENE THERAPY |
US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
CA2224907A1 (en) | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
DK0870044T3 (en) * | 1995-12-01 | 2004-08-02 | Crucell Holland Bv | Regulated protein expression in stably transfected mammalian cells |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
WO1998021350A1 (en) * | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
CA2274146C (en) | 1996-12-05 | 2007-02-06 | Introgene B.V. | Genetic modification of primate hemopoietic repopulating stem cells |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
EP0973866A4 (en) | 1997-03-04 | 2000-04-19 | Baxter Int | Adenovirus e1-complementing cell lines |
US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
FR2774699B1 (en) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | METHOD FOR REDUCING HOMOLOGATED RECOMBINATION EVENTS |
WO1999027123A2 (en) * | 1997-11-26 | 1999-06-03 | Board Of Regents, The University Of Texas System | Modified sv40 viral vectors |
WO1999032647A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
CA2319112C (en) | 1998-02-13 | 2003-10-28 | Genetrace Systems, Inc. | Use of ribozymes for functionating genes |
US5981225A (en) * | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
EP0959136A1 (en) | 1998-05-20 | 1999-11-24 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
JP2002528087A (en) * | 1998-10-27 | 2002-09-03 | クルセル ホランド ベー ヴェー | Improved AAV vector production |
IT1302403B1 (en) * | 1998-11-06 | 2000-09-05 | Angeletti P Ist Richerche Bio | CELLS FOR THE PRODUCTION OF DEFECTIVE ADENOVIRAL VECTORS, METHOD FOR THEIR PREPARATION AND USE. |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
IL133032A (en) * | 1998-11-20 | 2007-06-03 | Introgene Bv | Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells |
EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
US6869936B1 (en) | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
DE60039683D1 (en) * | 1999-03-04 | 2008-09-11 | Crucell Holland Bv | USE OF AN ADENOVIRUS VECTOR FOR THE TRANSDUCTION OF SYNOVIAL CELLS |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US20060099685A1 (en) * | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
CN100457914C (en) † | 1999-04-15 | 2009-02-04 | 荷兰克鲁塞尔公司 | Recombinant protein production in human cell using sequences encoding adenovirus E1 protein |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
CA2371069A1 (en) * | 1999-04-23 | 2001-02-01 | Crucell Holland B.V. | Means and methods for nucleic acid transfer |
ATE364707T1 (en) | 1999-05-17 | 2007-07-15 | Crucell Holland Bv | RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35 |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | Adenovirus carrying gag gene hiv vaccine |
EP1067190A1 (en) * | 1999-07-09 | 2001-01-10 | Introgene B.V. | Gene therapy for enhancing and/or inducing angiogenesis |
CA2384439A1 (en) * | 1999-09-10 | 2001-03-22 | Crucell Holland B.V. | Modified adenoviral vectors for use in gene therapy |
EP1083228A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
EP1083229A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
DE19955558C2 (en) * | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanent amniocyte cell line, its production and use for the production of gene transfer vectors |
US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
AU1817401A (en) * | 1999-12-14 | 2001-06-25 | Genovo, Incorporated | Methods and compositions for the manufacture of replication incompetent adenovirus |
CA2396779A1 (en) * | 2000-01-07 | 2001-07-12 | Stichting Klinishce Farmacologie Groningen | Gene therapy to promote angiogenesis and/or the treatment of heart failure |
US7132277B1 (en) | 2000-01-31 | 2006-11-07 | Merck & Co., Inc. | Helper dependent vector system for gene therapy |
AU2001245944B2 (en) | 2000-03-24 | 2007-01-18 | Cell Genesys, Inc. | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
KR20010064682A (en) * | 2000-07-01 | 2001-07-11 | 김재호 | Double Suicide Gene System using E1B attenuated adenovirus |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
EP1365794A2 (en) | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
US20040101957A1 (en) * | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
NZ524743A (en) * | 2000-09-20 | 2004-07-30 | Crucell Holland B | Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein |
DE60138403D1 (en) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST |
US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
CA2439185A1 (en) * | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constructs |
JP2004533815A (en) | 2001-03-14 | 2004-11-11 | ミリアド・ジェネティックス・インコーポレイテッド | TSG101-GAG interaction and use thereof |
EP1256803A1 (en) | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Methods for the identification of antiviral compounds |
US6682929B2 (en) | 2001-07-23 | 2004-01-27 | Genvec, Inc. | Adenovector complementing cells |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US20030119771A1 (en) * | 2001-08-22 | 2003-06-26 | Rompaey Luc Van | Modulators of bone homeostasis identified in a high-throughput screen |
DK1436397T3 (en) * | 2001-10-11 | 2010-08-09 | Merck Sharp & Dohme | Hepatitis C virus vaccine |
ES2344253T3 (en) | 2001-10-11 | 2010-08-23 | MERCK SHARP & DOHME CORP. | VACCINE AGAINST THE VIRUS OF HEPATITIS C. |
JP4583029B2 (en) | 2001-10-29 | 2010-11-17 | クルセル ホランド ベー ヴェー | Method and method for producing a protein having a predetermined post-translational modification |
CN100547069C (en) * | 2001-12-07 | 2009-10-07 | 克鲁塞尔荷兰公司 | The production of virus, viral isolates and vaccine |
DK1456238T3 (en) * | 2001-12-17 | 2008-08-18 | Crucell Holland Bv | Production of F (ab ') 2 fragments in mammalian cells |
US20030165954A1 (en) | 2002-01-09 | 2003-09-04 | Third Wave Technologies, Inc. | Cancer profiles |
JP4488290B2 (en) * | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | Fiber shaft mutation for efficient targeting |
EP1474533B1 (en) * | 2002-02-20 | 2006-04-26 | Merck & Co., Inc. | Method of determining adenovirus particle concentration |
CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
CA2478901A1 (en) * | 2002-03-29 | 2003-10-16 | Merck & Co., Inc. | Methods of virus production |
WO2003087348A1 (en) * | 2002-04-08 | 2003-10-23 | The Johns Hopkins University | Packaging cell line for diphtheria toxin expressing non-replicating adenovirus |
EA010828B1 (en) * | 2002-04-25 | 2008-12-30 | Круселл Холланд Б.В. | Recombinant adenovirus vectors and methods for the production thereof and use |
IL164802A0 (en) * | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
US20030219696A1 (en) * | 2002-05-23 | 2003-11-27 | Moreland Gerald W. | Method and apparatus for preventing backflow in dental saliva evacuators |
JP5139626B2 (en) | 2002-06-14 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | Monoclonal antibody hPAM4 |
US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US20080153083A1 (en) * | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
US20050221493A1 (en) * | 2002-12-04 | 2005-10-06 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
ATE354645T1 (en) * | 2002-12-20 | 2007-03-15 | Chromagenics Bv | MEANS AND METHODS FOR PRODUCING A PROTEIN THROUGH CHROMATIN OPENERS WHICH CAN MAKE CHROMATIN MORE ACCESSIBLE TO TRANSCRIPTION FACTORS |
EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
US20070212675A1 (en) * | 2003-04-15 | 2007-09-13 | Novartis Ag | Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof |
WO2004092397A2 (en) * | 2003-04-15 | 2004-10-28 | Novartis Ag | Tmprss2 regulatory sequences and uses thereof |
WO2004099396A1 (en) * | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
DK1626992T3 (en) * | 2003-05-23 | 2010-09-20 | Crucell Holland Bv | Production of recombinant IgM in PER.C6 cells |
US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
US7026164B2 (en) | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
CN1863918B (en) * | 2003-10-02 | 2011-03-30 | 克鲁塞尔荷兰公司 | Packaging cells for recombinant adenovirus |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
CA2545815A1 (en) | 2003-11-14 | 2005-06-09 | Genvec, Inc. | Adenoviral vectored tnf-a and chemoradiation to treat cancer |
WO2005071093A2 (en) | 2004-01-23 | 2005-08-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Chimpanzee adenovirus vaccine carriers |
US20050232927A1 (en) * | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
JP2007522814A (en) * | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | Virus purification method |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
WO2005110492A2 (en) | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
WO2005115477A2 (en) * | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
EP1773303A2 (en) * | 2004-05-25 | 2007-04-18 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
EP1784493A2 (en) * | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
JP4944032B2 (en) | 2004-09-13 | 2012-05-30 | ジェンザイム・コーポレーション | Multimeric construct |
PT1807009E (en) | 2004-10-05 | 2015-02-25 | Univ California | Stepped cannula |
US8563511B2 (en) | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
EP1805213B1 (en) * | 2004-10-28 | 2015-11-18 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
ES2384391T3 (en) | 2004-11-08 | 2012-07-04 | Chromagenics B.V. | Selection of host cells that express protein at high levels |
US8039230B2 (en) * | 2004-11-08 | 2011-10-18 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
MX2007004595A (en) * | 2004-11-08 | 2007-08-15 | Chromagenics Bv | Selection of host cells expressing protein at high levels. |
US8999667B2 (en) * | 2004-11-08 | 2015-04-07 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
US20060195935A1 (en) | 2004-11-08 | 2006-08-31 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
CA2590943C (en) * | 2004-12-13 | 2013-10-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
EP1856526A4 (en) | 2005-01-20 | 2008-11-12 | Univ Rochester | Thioredoxin interacting protein (txnip) as regulator of vascular function |
AU2006212885A1 (en) * | 2005-02-11 | 2006-08-17 | Merck & Co., Inc. | Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby |
ES2317517T5 (en) * | 2005-04-11 | 2016-01-21 | Crucell Holland B.V. | Virus purification using ultrafiltration |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
US8524678B2 (en) | 2005-05-31 | 2013-09-03 | The Regents Of The University Of Colorado, A Body Corporate | Method for delivering genes |
AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006135886A2 (en) * | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2610919C (en) | 2005-06-17 | 2013-09-10 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hepatitis c virus nucleic acid vaccine |
AU2006271666B2 (en) * | 2005-07-22 | 2011-04-07 | Crucell Holland B.V. | Cell line for producing coronaviruses |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
EP1929021A2 (en) | 2005-08-31 | 2008-06-11 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US7718369B2 (en) | 2005-09-12 | 2010-05-18 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
WO2007047907A2 (en) * | 2005-10-14 | 2007-04-26 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
AU2006308847C1 (en) * | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
JP2009513708A (en) | 2005-10-31 | 2009-04-02 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for diagnosis and treatment of cancer |
BRPI0618441B8 (en) | 2005-11-10 | 2021-07-27 | Genvec Inc | adenoviral vector |
EP1974044B1 (en) * | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
AR059089A1 (en) | 2006-01-20 | 2008-03-12 | Genzyme Corp | INTRAVENTRICULAR ADMINISTRATION OF AN ENZYME FOR LISOSOMAL STORAGE DISEASES |
CA3168881A1 (en) | 2006-02-09 | 2007-08-23 | Genzyme Corporation | Slow intraventricular delivery |
WO2008121102A2 (en) * | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US7968700B2 (en) * | 2006-03-20 | 2011-06-28 | Chromagenics B.V. | Expression augmenting DNA fragments, use thereof, and methods for finding thereof |
DE602007005366D1 (en) * | 2006-04-07 | 2010-04-29 | Chimeros Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF B-CELL MALIGNOMES |
ES2643469T3 (en) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Antibodies that bind to the human tyrosine phosphatase beta protein (HPTP-beta) and uses thereof |
EP2377953A1 (en) | 2006-06-23 | 2011-10-19 | Myriad Genetics, Inc. | DPYD gene variants and use thereof |
WO2007149594A2 (en) * | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
SI2634242T1 (en) | 2006-07-14 | 2017-07-31 | Patheon Holdings I B.V. | Improved process for the culturing of cells |
JP2009543868A (en) | 2006-07-17 | 2009-12-10 | クインテセンス バイオサイエンシーズ インコーポレーティッド | Methods and compositions for cancer treatment |
WO2008030605A2 (en) * | 2006-09-08 | 2008-03-13 | The Regents Of The University Of Michigan | Herv group ii viruses in lymphoma and cancer |
EP2114445A2 (en) * | 2007-01-09 | 2009-11-11 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US11371194B2 (en) * | 2007-01-19 | 2022-06-28 | Brock Usa, Llc | Base for turf system |
WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
DE602008004476D1 (en) * | 2007-03-09 | 2011-02-24 | Vectorlogics Inc | CELLS FOR ADENOVIRUS VECTOR AND PROTEIN PRODUCTION |
CA2683063A1 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
WO2009009432A2 (en) | 2007-07-06 | 2009-01-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
WO2009026152A1 (en) | 2007-08-16 | 2009-02-26 | The Regents Of The University Of Michigan | Metabolomic profiling of prostate cancer |
DE102007041655A1 (en) | 2007-09-03 | 2009-03-05 | Medicyte Gmbh | Propagation of primary cells and their use |
CA2702043A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
TWI488640B (en) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | Pharmaceutical preparation |
US8518884B2 (en) | 2008-04-25 | 2013-08-27 | Northwestern University | Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor |
US8193151B2 (en) * | 2008-04-25 | 2012-06-05 | Northwestern University | Methods for treating atrial or ventricular arrhythmias |
KR101639454B1 (en) * | 2008-07-15 | 2016-07-13 | 크루셀 홀란드 비.브이. | Scalable process for culturing per.c6 cells and producing products therefrom |
EP2342321B1 (en) | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
BRPI0919473A2 (en) | 2008-09-26 | 2017-08-29 | Oncomed Pharm Inc | FRIZZLED BINDING AGENTS AND THEIR USES |
WO2010039985A1 (en) | 2008-10-01 | 2010-04-08 | Quintessence Biosciences, Inc. | Therapeutic Ribonucleases |
US20110184154A1 (en) * | 2008-10-17 | 2011-07-28 | Percivia Llc | Cell broth clarification and host cell protein removal |
CN102203242B (en) * | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | Method for the production of adenoviral vectors |
CA2749113A1 (en) | 2009-01-09 | 2010-07-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
US20110312525A1 (en) | 2009-01-20 | 2011-12-22 | Bruce Acres | Soluble icam-1 as biomarker for prediction of therapeutic response |
WO2010107991A2 (en) | 2009-03-18 | 2010-09-23 | Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer |
MX2011010061A (en) | 2009-03-24 | 2011-11-18 | Transgene Sa | Biomarker for monitoring patients. |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
US20120058493A1 (en) | 2009-04-17 | 2012-03-08 | Bruce Acres | Biomarker for monitoring patients |
CA2756591C (en) | 2009-04-23 | 2018-11-06 | Crucell Holland B.V. | Recombinant human alpha1-antitrypsin |
US8748386B2 (en) | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
CA2748765C (en) | 2009-07-06 | 2014-07-22 | Akebia Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
EP2451935A2 (en) | 2009-07-08 | 2012-05-16 | Glycotope GmbH | Perfusion bioreactor |
CN102483405B (en) | 2009-07-10 | 2015-12-02 | 特朗斯吉有限公司 | For selecting biomarker and the correlation technique of patient |
CA2763091C (en) | 2009-07-16 | 2019-07-23 | Crucell Holland B.V. | Production of polio virus at high titers for vaccine production |
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
EA028623B1 (en) | 2009-10-15 | 2017-12-29 | Янссен Вэксинс Энд Превеншн Б.В. | Method for the purification of adenovirus particles |
JP5465331B2 (en) * | 2009-10-15 | 2014-04-09 | クルセル ホランド ベー ヴェー | Method for purifying adenovirus from high cell density cultures |
US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
KR20120139672A (en) | 2009-11-09 | 2012-12-27 | 젠벡, 인코포레이티드 | Methods of propagating monkey adenoviral vectors |
EP2521566B1 (en) | 2010-01-08 | 2014-09-03 | ProFibrix BV | Fibrinogen preparations enriched in fibrinogen with an extended alpha chain |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
CN102762721B (en) | 2010-02-15 | 2015-03-11 | 克鲁塞尔荷兰公司 | Method for the production of Ad26 adenoviral vectors |
WO2011116189A1 (en) | 2010-03-17 | 2011-09-22 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
EP2548025A4 (en) * | 2010-03-17 | 2013-09-25 | Univ Michigan | Using phage epitopes to profile the immune response |
EP3284821B1 (en) | 2010-03-23 | 2022-01-05 | Precigen, Inc. | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
DE102010041958A1 (en) | 2010-10-04 | 2012-04-05 | Medicyte Gmbh | Suitable hepatocytes for in vitro genotoxicity tests |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
US20130344053A1 (en) | 2010-12-28 | 2013-12-26 | University Of Rochester | Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
HUE030501T2 (en) | 2011-07-06 | 2017-05-29 | Sykehuset Sorlandet Hf | Egfr targeted therapy |
TWI575070B (en) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv polymerase mutants |
EP3741384A1 (en) | 2011-09-07 | 2020-11-25 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
AU2012305714A1 (en) | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
TW201318637A (en) | 2011-09-29 | 2013-05-16 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis C virus infection |
EP2764011B1 (en) | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
CA2851251C (en) | 2011-10-05 | 2023-09-12 | Genvec, Inc. | Simian (gorilla) adenovirus or adenoviral vectors and methods of use |
WO2013052799A2 (en) | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vectors and methods of use |
BR112014008249B1 (en) | 2011-10-05 | 2022-03-15 | Genvec Inc | Adenovirus or adenoviral vector and composition with the same |
EP2780034A1 (en) | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
JP5969044B2 (en) | 2011-11-24 | 2016-08-10 | バイロメッド カンパニー リミテッド | Adenovirus-producing new cell line and its use |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
CN104136613B (en) | 2011-12-08 | 2017-12-29 | 威洛克有限公司 | Carrier, method with virulent gene and application thereof |
WO2013116591A1 (en) | 2012-02-02 | 2013-08-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccine |
NZ627992A (en) | 2012-02-07 | 2017-02-24 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
ES2582504T3 (en) | 2012-03-12 | 2016-09-13 | Crucell Holland B.V. | Lots of recombinant adenovirus with altered ends |
KR102050616B1 (en) | 2012-03-22 | 2019-12-03 | 얀센 백신스 앤드 프리벤션 비.브이. | Vaccine against rsv |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
US9790519B2 (en) | 2012-05-29 | 2017-10-17 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
WO2013180967A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Herpes simplex virus vaccine |
KR20150058152A (en) | 2012-07-10 | 2015-05-28 | 트랜스진 에스아이 | Mycobacterial antigen vaccine |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
US9982240B2 (en) | 2012-08-03 | 2018-05-29 | Sanofi Pasteur | Production of infectious influenza viruses |
EP2890720B1 (en) | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
JP2015536933A (en) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods of treating neuroendocrine tumors using Wnt pathway binding agents |
CN105051198A (en) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | Recombinant adenoviruses and use thereof |
KR102228358B1 (en) | 2012-12-21 | 2021-03-16 | 쉬케후세트 솔란데트 에이치에프 | Egfr targeted therapy of neurological disorders and pain |
CN105073195A (en) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
KR101606910B1 (en) | 2013-03-29 | 2016-04-04 | 충북보건과학대학교 산학협력단 | A549 Based Cell Line for Preparing Adenovirus Vector |
SG10201912901YA (en) | 2013-04-17 | 2020-02-27 | Genzyme Corp | Compositions and methods for treating and preventing macular degeneration |
WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
MY181066A (en) | 2013-04-25 | 2020-12-17 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
EP3848044A1 (en) | 2013-05-21 | 2021-07-14 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
KR102313153B1 (en) | 2013-06-17 | 2021-10-15 | 얀센 백신스 앤드 프리벤션 비.브이. | Stabilized soluble pre-fusion rsv f polypeptides |
ES2525768B1 (en) * | 2013-06-24 | 2015-10-07 | Curaxis, S.L. | Procedure for the production of glycosylated recombinant proteins. |
JP6297692B2 (en) | 2013-08-08 | 2018-03-20 | グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. | Clamp device for minimally invasive treatment and use thereof |
AP2016009154A0 (en) | 2013-09-19 | 2016-04-30 | Crucell Holland Bv | Improved adenovirus formulations |
SG10201808061WA (en) | 2013-09-30 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Method for the clarification of high density crude cell culture harvest |
US10765731B2 (en) | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
TWI687225B (en) | 2014-02-06 | 2020-03-11 | 美商健臻公司 | Compositions and methods for treating and preventing macular degeneration |
EP2927685A1 (en) | 2014-04-02 | 2015-10-07 | Medicyte GmbH | Suitable hepatocytes for in-vitro hepatitis tests |
US10294460B2 (en) | 2014-07-24 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
MX2017002934A (en) | 2014-09-07 | 2017-05-30 | Selecta Biosciences Inc | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses. |
WO2016044707A1 (en) | 2014-09-18 | 2016-03-24 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
TWI710635B (en) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | Adenoviral vector encoding human atonal homolog-1 (hath1) |
CN107075521B (en) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | Therapeutic HPV16 vaccine |
EP3259374B1 (en) | 2015-02-19 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Method for quantification of virus particles using capillary zone electrophoresis. |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
EP3271729B1 (en) | 2015-03-18 | 2020-09-23 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
SI3283634T1 (en) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
US20180112006A1 (en) | 2015-04-17 | 2018-04-26 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
CN114366802A (en) | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | Enterally delivered bitter oligopeptides for the treatment of type 2 diabetes |
KR20180026734A (en) | 2015-07-07 | 2018-03-13 | 얀센 백신스 앤드 프리벤션 비.브이. | Stabilized soluble fusion-pre-RSV F polypeptide |
EA039065B1 (en) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Vaccine against rsv |
EP3337500A1 (en) | 2015-08-20 | 2018-06-27 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv18 vaccines |
EA036412B1 (en) | 2015-10-06 | 2020-11-09 | Янссен Вэксинс Энд Превеншн Б.В. | Method for protecting an adenovirus from plastic-induced degradation and use of 2-hydroxypropyl--cyclodextrin for protecting the adenovirus |
WO2017074517A1 (en) * | 2015-10-30 | 2017-05-04 | Seracare Life Sciences, Inc. | Adenovirus control virus |
US10377801B2 (en) | 2015-11-04 | 2019-08-13 | Northwestern University | Amelioration of chronic kidney disease |
US11273151B2 (en) | 2015-11-04 | 2022-03-15 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
SG11201807913XA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
MY193584A (en) | 2016-04-05 | 2022-10-19 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
EP3448881B1 (en) | 2016-04-26 | 2023-06-07 | Icahn School of Medicine at Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
JP7053491B2 (en) | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Therapeutic HPV vaccine combination |
EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
KR102573534B1 (en) | 2016-05-12 | 2023-08-31 | 얀센 백신스 앤드 프리벤션 비.브이. | Strong and balanced bidirectional promoter |
ES2836598T3 (en) | 2016-05-30 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Stabilized prefusion RSV F proteins |
US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018013509A1 (en) | 2016-07-11 | 2018-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for diagnosing and treating arrhythmias |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
US11155832B2 (en) | 2016-09-30 | 2021-10-26 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into T cells |
EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
JP2020506890A (en) | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | Patterned administration of immunosuppressants coupled to synthetic nanocarriers |
WO2018140630A1 (en) | 2017-01-25 | 2018-08-02 | Northwestern University | Autophagy inducers for treatment of cns conditions |
CA3053212C (en) | 2017-02-09 | 2021-04-13 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
CN110914413A (en) | 2017-02-17 | 2020-03-24 | 隆萨有限公司 | Mammalian cell producing adeno-associated virus |
KR102122117B1 (en) | 2017-04-21 | 2020-06-11 | (주)지뉴인텍 | A Cell Line for Producing Adenovirus having limitedautoreplication capability and A Method of the same |
JP2020519663A (en) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
MX2020002876A (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv. |
CA3078705A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
MX2020004490A (en) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof. |
MX2020004487A (en) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof. |
SG11202003200VA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
KR20200074987A (en) | 2017-10-31 | 2020-06-25 | 얀센 백신스 앤드 프리벤션 비.브이. | Adenovirus and uses thereof |
AU2018372906A1 (en) | 2017-11-22 | 2020-06-11 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
EP3723771A4 (en) | 2017-12-11 | 2022-04-06 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
WO2019145310A1 (en) | 2018-01-23 | 2019-08-01 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
SG11202008508QA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Hepatitis b vaccines and uses of the same |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
US20220204567A1 (en) | 2019-04-25 | 2022-06-30 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
KR20220008875A (en) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | Co-administration of seasonal influenza vaccine and adenovirus-based respiratory syncytial virus vaccine |
EA202193119A1 (en) | 2019-05-15 | 2022-02-18 | Янссен Вэксинс Энд Превеншн Б.В. | PREVENTIVE TREATMENT OF RESPIRATORY SYNCYTHIAL VIRUS INFECTION WITH ADENOVIRUS VACCINE |
EP3969046A1 (en) | 2019-05-16 | 2022-03-23 | Janssen Vaccines & Prevention B.V. | Methods for inducing a safe immune response against polio virus |
JP2022534741A (en) | 2019-05-28 | 2022-08-03 | セレクタ バイオサイエンシーズ インコーポレーテッド | Methods and compositions for attenuated antiviral transduction vector immune response |
EP4025247A1 (en) | 2019-09-05 | 2022-07-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
CN114710957A (en) | 2019-10-03 | 2022-07-05 | 扬森疫苗与预防公司 | Adenovirus vectors and uses thereof |
MX2022005980A (en) | 2019-11-18 | 2022-09-07 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses. |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
CN115484978A (en) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | Methods and compositions for treating cancer using immune cells |
JP2023521194A (en) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク,インコーポレーテツド | PSMA and STEAP1 vaccines and their uses |
CA3172618A1 (en) | 2020-04-21 | 2021-10-28 | Jjp Biologics Sp. Z O.O. | Humanized anti-human cd89 antibodies and uses thereof |
WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
US20230029453A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
JP2023533584A (en) | 2020-07-13 | 2023-08-03 | トランジェーヌ | treatment of immunosuppression |
EP4196137A1 (en) | 2020-08-11 | 2023-06-21 | Musculoskeletal Transplant Foundation | Method for treating cardiac conditions with placenta-derived compositions |
WO2023017494A1 (en) | 2021-08-13 | 2023-02-16 | Triovance Holding Llc | A skin substitute composition and methods of producing and using the same |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US545522A (en) * | 1895-09-03 | Vehicle-wheel | ||
US4497796A (en) | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
US4727028A (en) | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5208149A (en) | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4740463A (en) | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
FR2573436B1 (en) | 1984-11-20 | 1989-02-17 | Pasteur Institut | RECOMBINANT DNA COMPRISING A NUCLEOTIDE SEQUENCE ENCODING A DETERMINED POLYPEPTIDE UNDER THE CONTROL OF AN ADENOVIRUS PROMOTER, VECTORS CONTAINING THIS RECOMBINANT DNA, EUKARYOT CELLS TRANSFORMED BY THIS RECOMBINANT DNA, THE CONSTITUTION OF VACCINES |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5744133A (en) | 1986-08-13 | 1998-04-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor |
US6007806A (en) | 1986-08-13 | 1999-12-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor |
US4835260A (en) | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5378618A (en) * | 1988-04-15 | 1995-01-03 | E. I. Du Pont De Nemours And Company | Vitro headful packaging system for cloning DNA fragments as large as 95kb |
US5192539A (en) | 1988-07-21 | 1993-03-09 | Akzo N.V. | Infectious bursal disease virus production in continuous cell lines |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2000048A1 (en) * | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
GB8900483D0 (en) | 1989-01-10 | 1989-03-08 | Celltech Ltd | Recombinant dna method |
US5223394A (en) * | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
DE3923963A1 (en) | 1989-07-20 | 1991-01-31 | Behringwerke Ag | MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5545522A (en) * | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
US6743623B2 (en) | 1991-09-27 | 2004-06-01 | Centre National De La Recherche Scientifique | Viral recombinant vectors for expression in muscle cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
CA2053187A1 (en) | 1991-10-10 | 1993-04-11 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
US5518913A (en) | 1991-10-10 | 1996-05-21 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
US5384249A (en) | 1991-12-17 | 1995-01-24 | Kyowa Hakko Kogyo Co., Ltd. | α2→3 sialyltransferase |
ES2312164T3 (en) | 1992-09-25 | 2009-02-16 | Aventis Pharma S.A. | ADENOVIRUS VECTORS FOR THE TRANSFER OF STRANGE GENES IN CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN THE BRAIN. |
ATE307212T1 (en) | 1992-11-18 | 2005-11-15 | Arch Dev Corp | ADENOVIRUS-DIRECTED GENE TRANSFER TO THE HEART AND VASCULAR SMOOTH MUSCLE |
EP1024198A3 (en) * | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
DK0604684T3 (en) | 1992-12-23 | 1998-01-26 | Campina Melkunie Bv | Process for Recovery of Alphalactalbumin and Betalactoglobulin from a Milk Protein Product |
DE4311651A1 (en) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
JPH09500782A (en) * | 1993-04-08 | 1997-01-28 | ジェネティック セラピー,インコーポレイテッド | Adenovirus vector containing DNA encoding lung surfactant protein |
FR2704234B1 (en) | 1993-04-22 | 1995-07-21 | Centre Nat Rech Scient | RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY. |
FR2705361B1 (en) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Viral vectors and use in gene therapy. |
US6133028A (en) * | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
FR2705686B1 (en) * | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
US5919676A (en) * | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
ATE304604T1 (en) * | 1993-06-24 | 2005-09-15 | Frank L Graham | ADENOVIRUS VECTORS FOR GENE THERAPY |
ES2310924T3 (en) * | 1993-07-13 | 2009-01-16 | Centelion | DEFECTIVE ADENOVIRAL VECTORS AND USE IN GENE THERAPY. |
FR2707664B1 (en) | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Viral vectors and use in gene therapy. |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) * | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
US5658763A (en) | 1993-10-25 | 1997-08-19 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
US20010006629A1 (en) | 1993-10-25 | 2001-07-05 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
US6210939B1 (en) * | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
US6057299A (en) | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
CA2117668C (en) | 1994-03-09 | 2005-08-09 | Izumu Saito | Recombinant adenovirus and process for producing the same |
AU2194895A (en) | 1994-03-25 | 1995-10-17 | Uab Research Foundation, The | Composition and methods for creating syngeneic recombinant virus-producing cells |
US5789247A (en) | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
AU693545B2 (en) | 1994-04-26 | 1998-07-02 | Chugai Seiyaku Kabushiki Kaisha | Melt granulated sucralfate preparations and a process for their production |
ATE336587T1 (en) * | 1994-06-10 | 2006-09-15 | Genvec Inc | ADENOVIRUS VECTOR SYSTEMS AND CELL LINES |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
FR2721943B1 (en) | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE |
US6204052B1 (en) * | 1994-08-16 | 2001-03-20 | Introgene B.V. | Adenoviral vectors with reduced TNF response and partial E3 region deletion |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
FR2725726B1 (en) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | VIRAL VECTORS AND USE IN GENE THERAPY |
FR2726285B1 (en) | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE |
WO1996013597A2 (en) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Improved adenovirus and methods of use thereof |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
CA2206205A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors |
CA2206683A1 (en) * | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
FR2727867B1 (en) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS |
GB9500659D0 (en) | 1995-01-13 | 1995-03-08 | Camco Drilling Group Ltd | Improvements in or relating to rotary drill bits |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US5652224A (en) * | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
ATE243260T1 (en) * | 1995-04-17 | 2003-07-15 | Univ Texas | ADENOVIRUS HELPER VIRUS SYSTEM |
JPH08303576A (en) | 1995-05-10 | 1996-11-19 | Aisin Seiki Co Ltd | Shift control device for automatic transmission |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
ATE445705T1 (en) * | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUSES FOR GENE THERAPY |
FR2735789B1 (en) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
US7001764B2 (en) | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
FR2737222B1 (en) * | 1995-07-24 | 1997-10-17 | Transgene Sa | NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY |
FR2737501B1 (en) * | 1995-07-31 | 1997-10-24 | Transgene Sa | NOVEL AUXILIARY VIRUSES FOR THE PREPARATION OF RECOMBINANT VIRAL VECTORS |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
EA003195B1 (en) | 1995-11-13 | 2003-02-27 | Такара Сузо Ко., Лтд. | Method for gene transfer into target cells with retrovirus |
DK0870044T3 (en) * | 1995-12-01 | 2004-08-02 | Crucell Holland Bv | Regulated protein expression in stably transfected mammalian cells |
US5871727A (en) * | 1995-12-08 | 1999-02-16 | Uab Research Foundation | Targeted adenovirus vectors |
AU731615B2 (en) * | 1996-02-09 | 2001-04-05 | Het Nederlands Kanker Instituut | Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells |
US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
US5891690A (en) * | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
EP0856585A1 (en) * | 1997-01-29 | 1998-08-05 | Introgene B.V. | A conditional replication and expression system |
WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
WO1998039035A1 (en) * | 1997-03-07 | 1998-09-11 | The Wistar Institute Of Anatomy & Biology | Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue |
CA2221819A1 (en) | 1997-03-27 | 1998-09-27 | Thomas A. Gigliatti | Insect expression vectors |
US5981275A (en) | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
AU743051B2 (en) | 1997-05-08 | 2002-01-17 | Genetic Therapy, Inc. | Gene transfer with adenoviruses having modified fiber proteins |
US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
US6287857B1 (en) * | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
WO1999047180A1 (en) | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6413776B1 (en) * | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
EP1020529B1 (en) | 1998-11-20 | 2005-06-01 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
WO2003048197A1 (en) | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production and of viruses, viral isolates and vaccines |
ATE364707T1 (en) | 1999-05-17 | 2007-07-15 | Crucell Holland Bv | RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35 |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7125705B2 (en) | 2000-04-28 | 2006-10-24 | Genzyme Corporation | Polynucleotides for use in recombinant adeno-associated virus virion production |
EP1157999A1 (en) | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
US6844192B2 (en) | 2001-06-29 | 2005-01-18 | Wake Forest University | Adenovirus E4 protein variants for virus production |
US20030026783A1 (en) | 2001-08-03 | 2003-02-06 | Amine Abina | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins |
JP4583029B2 (en) | 2001-10-29 | 2010-11-17 | クルセル ホランド ベー ヴェー | Method and method for producing a protein having a predetermined post-translational modification |
CN100547069C (en) | 2001-12-07 | 2009-10-07 | 克鲁塞尔荷兰公司 | The production of virus, viral isolates and vaccine |
IL164802A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
EA010828B1 (en) | 2002-04-25 | 2008-12-30 | Круселл Холланд Б.В. | Recombinant adenovirus vectors and methods for the production thereof and use |
SI1523496T1 (en) | 2002-07-18 | 2011-11-30 | Merus B V | Recombinant production of mixtures of antibodies |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
WO2004099396A1 (en) | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
JP2007522814A (en) | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | Virus purification method |
US20080131461A1 (en) | 2004-10-14 | 2008-06-05 | Crucell Holland B.V. | Malaria Prime/Boost Vaccines |
US20070010016A1 (en) | 2005-03-11 | 2007-01-11 | Mccelland Alan | Gene transfer with adenoviruses having modified fiber proteins |
-
1996
- 1996-06-14 AT AT04101716T patent/ATE445705T1/en active
- 1996-06-14 AU AU60182/96A patent/AU731767B2/en not_active Expired
- 1996-06-14 ES ES96917735T patent/ES2231813T5/en not_active Expired - Lifetime
- 1996-06-14 DK DK96917735.1T patent/DK0833934T4/en active
- 1996-06-14 IL IL12261496A patent/IL122614A0/en unknown
- 1996-06-14 EP EP96917735A patent/EP0833934B2/en not_active Expired - Lifetime
- 1996-06-14 US US08/793,170 patent/US5994128A/en not_active Expired - Lifetime
- 1996-06-14 CA CA2222140A patent/CA2222140C/en not_active Expired - Lifetime
- 1996-06-14 PT PT04101716T patent/PT1445322E/en unknown
- 1996-06-14 DE DE69633565T patent/DE69633565T3/en not_active Expired - Lifetime
- 1996-06-14 WO PCT/NL1996/000244 patent/WO1997000326A1/en active Search and Examination
- 1996-06-14 DE DE69638058T patent/DE69638058D1/en not_active Expired - Lifetime
- 1996-06-14 ES ES04101716T patent/ES2333425T5/en not_active Expired - Lifetime
- 1996-06-14 AT AT96917735T patent/ATE278794T1/en active
- 1996-06-14 SI SI9630772T patent/SI1445322T2/en unknown
- 1996-06-14 SI SI9630698T patent/SI0833934T2/en unknown
- 1996-06-14 IL IL16040696A patent/IL160406A0/en active IP Right Grant
- 1996-06-14 PT PT96917735T patent/PT833934E/en unknown
- 1996-06-14 EP EP04101716A patent/EP1445322B2/en not_active Expired - Lifetime
- 1996-06-14 JP JP50294897A patent/JP4051416B2/en not_active Expired - Lifetime
- 1996-06-14 KR KR1019970709411A patent/KR100449181B1/en active IP Right Grant
- 1996-06-14 DK DK04101716.1T patent/DK1445322T4/en active
- 1996-06-14 KR KR10-2004-7010409A patent/KR100470180B1/en active IP Right Grant
-
1997
- 1997-07-15 US US08/892,873 patent/US6033908A/en not_active Expired - Lifetime
-
1999
- 1999-04-23 US US09/298,745 patent/US6395519B1/en not_active Expired - Lifetime
- 1999-06-15 US US09/333,820 patent/US6306652B1/en not_active Expired - Lifetime
- 1999-06-16 US US09/334,765 patent/US6238893B1/en not_active Expired - Lifetime
-
2000
- 2000-02-17 US US09/506,548 patent/US6602706B1/en not_active Expired - Lifetime
-
2001
- 2001-10-23 US US10/038,271 patent/US20020151032A1/en not_active Abandoned
-
2002
- 2002-05-01 US US10/136,139 patent/US20020164802A1/en not_active Abandoned
-
2004
- 2004-02-15 IL IL160406A patent/IL160406A/en not_active IP Right Cessation
- 2004-09-14 HK HK04106971.6A patent/HK1064406A1/en not_active IP Right Cessation
-
2005
- 2005-05-19 US US11/134,674 patent/US8236293B2/en not_active Expired - Lifetime
-
2006
- 2006-08-22 JP JP2006225820A patent/JP2006345872A/en active Pending
-
2007
- 2007-07-16 US US11/879,421 patent/US20090023196A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2222140A1 (en) | Packaging systems for human recombinant adenovirus to be used in gene therapy | |
Gilmartin et al. | CPSF recognition of an HIV-1 mRNA 3'-processing enhancer: multiple sequence contacts involved in poly (A) site definition. | |
EP3216867B1 (en) | Method for modifying genome sequence to introduce specific mutation to targeted dna sequence by base-removal reaction, and molecular complex used therein | |
Pradhan et al. | Baculovirus-mediated expression and characterization of the full-length murine DNA methyltransferase | |
JP2019150033A (en) | Mutant cas9 proteins | |
Loeken et al. | Trans-activation of RNA polymerase II and III promoters by SV40 small t antigen | |
US6254862B1 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
JP2019122384A (en) | Rna guided transcriptional regulation | |
Chatterjee et al. | Adenoviral protein VII packages intracellular viral DNA throughout the early phase of infection. | |
US6913927B2 (en) | Non-adenoviral gene product-based complementing cells for adenoviral vectors | |
WO1995016048A3 (en) | Recombinant protein production in bovine adenovirus expression vector system | |
Terenzi et al. | The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors | |
Sussenbach | The structure of the genome | |
Weeks et al. | Adenovirus E3-early promoter: sequences required for activation by E1A | |
Yao et al. | High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells | |
Osborne et al. | Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication | |
Okada et al. | Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex | |
JP2004536607A5 (en) | ||
Hemström et al. | Adenovirus E4-dependent activation of the early E2 promoter is insufficient to promote the early-to-late-phase transition | |
CA2538025A1 (en) | Packaging cells for recombinant adenovirus | |
Brady et al. | Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus | |
AU3832699A (en) | Chimeric adenoviral vectors | |
Young et al. | The genetic system | |
Holz-Schietinger et al. | De novo DNA methyltransferase DNMT3A: Regulation of oligomeric state and mechanism of action in response to pH changes | |
KR20140012968A (en) | Modified human cmv promoters that are resistant to gene silencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20160614 |